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Bile salt-dependent lipase (BSDL), a 110 kDa glycoprotein
secreted by the pancreatic acinar cells, participates in the
duodenal hydrolysis of dietary lipid esters. Recent in vitro and
in vivo studies demonstrated that the BSDL reaches the blood
via a transcytosis motion through enterocytes, suggesting
that this enzyme may play a role in vascular biology. Once in
the blood, BSDL should be eliminated. We address the
hypothesis that BSDL may be filtered by the glomerulus and
eliminated in urines. Immunological methods and proteomic
were used to detect and to characterize BSDL in urine. The
immunoreactive form of BSDL was detected in urines of 36
male subjects devoid of renal failure. Proteomic
demonstrated that the immunoreactive protein is BSDL.
Experiments using a monoclonal antibody to the oncofetal
glycoform of pancreatic BSDL suggested that the protein is
not expressed by renal cells but originates from the pancreas
via circulation. We demonstrate that under normal
physiological conditions, BSDL, a high-molecular weight
blood glycoprotein, can be filtered by the renal glomerulus to
be eliminated in urines.
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Bile salt-dependent lipase (BSDL, E.C.3.1.1.13) is an enzyme
involved in the duodenal hydrolysis of cholesteryl esters.1,2
The enzyme is synthesized in the endoplasmic reticulum of
pancreatic acinar cells, then follows the secretory pathway of
these cells to be secreted as a component of the pancreatic
juice.3 Once in the duodenum, BSDL is activated by bile salts
and participates in the hydrolysis of dietary lipid esters.
However, a fraction of BSDL is internalized by enterocytes via
the oxidized low-density lipoprotein lectin-like receptor 1
(Lox-1) scavenger receptor4 and transported to the blood
compartment,5 where it partly associates with apolipoprotein
B-containing lipoproteins.6 BSDL was detected in athero-
sclerotic lesions of hypercholesterolemic monkeys and in the
human aortic endothelium.7,8 The role of BSDL in blood and
in part in atherosclerosis is still speculative.7–11
Following its entrance into the blood stream, BSDL should
be eliminated. This enzyme is a 110 kDa protein with a radius
of 53.4 A˚;12 consequently it cannot be theoretically cleared
from the circulation by renal filtration.13 Data suggested that
BSDL participates in the hepatic selective uptake of high-
density lipoproteins; therefore, one possibility is that blood
BSDL is partly eliminated via liver captation.14 The high-
density lipoprotein particle undergoes a retroendocytosis
process during which lipids are separated from the
holoparticle for delivery to the bile, whereas the protein
moiety is re-secreted in the circulation15 supporting the fact
that BSDL may not be eliminated by this way. Because BSDL
is a sialylated glycoprotein,3 another possibility is the liver
clearance of plasma asialoglycoproteins.16
In this study, we have examined the possible involvement
of the kidney in the clearance of blood BSDL. We demo-
nstrated that BSDL is present in urines of healthy subjects
and likely originates from the pancreas via circulation.
RESULTS
Immunoreactivity of urine from healthy subjects
Morning urines were analyzed for their reactivity with
antibodies against pancreatic BSDL. Urines were centrifu-
gated to eliminate cell debris and other insoluble elements,
then 25 ml of each sample was analyzed on sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
and electrotransferred onto nitrocellulose membranes.
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Membranes were probed with the pAbL64 or with the
mAb8H8. All urines were reactive to these antibodies and a
protein can be immunodetected at 110 kDa. This mass
corresponds to that of the human pancreatic BSDL.3 Figure 1
displays results obtained for healthy subjects Nb 1–8 given as
an example. Along with a band at 110 kDa, some bands with
a higher migration can be detected with antibodies. This
could be because of a polymorphism of the immunoreactive
protein or degradation occurring during sample handling.
However, freeze–thawing cycles or urine incubation (24 h) at
371C followed by aliquot analyses on SDS-PAGE and
immunoblotting do not correlate with the degradation of
the pAbL64 immunoreactive protein (data not shown). This
favors a polymorphism of this protein in urines, which could
reflect that of the pancreatic BSDL.17,18
Characterization of BSDL in urine from healthy subjects
To demonstrate that the pAbL64 and mAb8H8 immuno-
reactive protein in urine is BSDL, 5 ml of concentrated urine
was desalted on Sephadex G-25. The eluted fractions
associated with an activity on 4-nitrophenyl caproate
(4-NPC) were also reactive with the mAb8H8, showing that
the immunoreactivity and the esterolytic activity are present
together in these fractions. The eluted fractions were pooled,
concentrated by lyophilization and dissolved in 1 ml Tris/HCl
buffer (10 mM, pH 7.8) 400 mM NaCl. The concentrated pool
was active on cholesteryl esters (12.171.5 pmol/min/ml).
This material was then loaded on a Sephacryl HRS-200
column. Fractions of 1 ml were collected after the void
volume (40 ml) of the column. The 4-NPC activity is still
associated with the pAbL64 reactivity (Figure 2). Eluted
fractions 78–90 containing both esterolytic activity and
immunoreactivity were pooled. At this stage, the specific
activity of the enzyme is increased by approximately 300%
(Table 1). The pooled fractions (12 ml) were dialyzed against
water at 41C and lyophilized. An SDS-PAGE showed a main
protein band at 110 kDa, which was reactive with pAbL64
(Figure 3). Same results were obtained with all urines
examined up to now.
These data support the presence of an active immuno-
reactive form of BSDL in urines of healthy subjects. To
ascertain that this protein is actually BSDL, the material
eluted from the molecular sieving column was loaded on a
large SDS-PAGE. One lane of this gel was electrotransferred
onto a nitrocellulose membrane and probed with pAbL64 to
detect the immunoreactive protein. Another lane was treated
with Coomassie blue, and the area of this band correspond-
ing to the immunoreactivity was cut into four slices
(Figure 4). A peptide mass fingerprinting was performed
on each slice.
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Figure 1 | Detection of an immunoreactive form of BSDL in urines
of healthy subjects. Morning urines from 36 healthy subjects (25 ml)
were analyzed on SDS-PAGE and immunodetection using (a)
polyclonal antibodies (pAbL64) or (b) a monoclonal antibody
(mAb8H8) to human BSDL. Only urines from subjects Nb 1–8 were
shown. Arrowheads (left) indicate the position of calibrated
molecular mass standard proteins and arrows (right) indicate the
apparent molecular size of BSDL detected in urines.
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Figure 2 | Molecular sieving of urines from healthy subjects. Five
milliliters of concentrated and desalted urines were loaded onto a
Sephacryl S-200 column (120 1.5 cm) eluted with 10 mM Tris/HCl
buffer (0.4 M NaCl) at 25 ml/h. Fractions (1 ml) were collected and
analyzed for immunoreactivity with the pAbL64 (K) and for
esterolytic activity on 4-NPC (J). The full line represents the
absorption of fraction at 280 nm. Fractions 78–90 associating the
immunoreactivity and the esterolytic activity were pooled (bar),
dialyzed against water and lyophilized.
Table 1 | Purification step of BSDL from healthy subjects
urines
Proteins
Esterolytic
activitya
Specific
activitya
Purification step (lg/ml) (10–3 U/ml) (U/mg)
Concentrated urines 28 104 258 1 103
Desalted fraction (Sephadex G25) 470 34 72 103
Molecular sieving (Sephacryl
HRS-200)
35 10 290 103
aActivities determined on 4-NPC.
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Figure 3 | SDS-PAGE and immunodetection analysis of the
material loaded and eluted from molecular sieving on Sephacryl
HRS-200. (a) SDS-PAGE of material loaded (lane 1) and eluted (lane 2)
from the column. Proteins were detected by Coomassie blue staining.
(b) Immunodetection using pAbL64 of the material loaded (lane 1)
and eluted (lane 2) from the column. Arrowheads (left) indicate the
position of calibrated molecular mass standard proteins and arrows
(right) indicate the apparent molecular size of BSDL detected in
urines.
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The matrix-assisted laser desorption ionization (MALDI)
mass spectrum of the digest of slice 1 (Figure 5, upper panels)
showed 12 peaks identified as tryptic peptides of BSDL. Slice
2 gave the same results, whereas not enough material was
detected in slices 3 and 4. The coverage of the BSDL sequence
(Figure 5, lower panel) is close to 20% and suggested that the
pAbL64 and mAb8H8 immunoreactive protein in urine is
actually BSDL. Taking into account that the O-glycosylated
C-terminal domain of BSDL (framed sequence in the lower
panel of Figure 5) cannot be digested by trypsin, the sequence
coverage (underlined sequence in the lower panel of Figure 5)
is satisfactory.
BSDL in urines is of pancreatic origin
The glycosylation of pancreatic BSDL differs from the
pathophysiological state of the pancreas, and BSDL expressed
by tumoral pancreas bears the oncofetal glycotope recognized
by mAbJ28.19 Any other tissue in humans even those
expressing BSDL, displayed this epitope.19,20 Therefore, urine
from a patient afflicted with pancreatic cancer was analyzed
on SDS-PAGE, transferred onto a nitrocellulose membrane
and probed with pAbL64, mAb8H8 and mAbJ28.
BSDL in this urine sample is reactive with pAbL64 and
mAb8H8 (Figure 6a). When the membrane was probed with
mAbJ28 (lane 3) or mAb8H8 (lane 2) instead of pAbL64
(lane 1), a reactivity associated with a protein around
110 kDa was detected. Therefore, BSDL present in urines
could harbor the J28 epitope, suggesting its pancreatic origin.
To support this particular point, BSDL has been immuno-
precipitated from desalted urines of this patient with the
pAbL64. Immunoprecipitated material was separated on
SDS-PAGE and electrotransferred on a nitrocellulose mem-
brane further probed with pAbL64, mAb8H8 or mAbJ28. The
pAbL64 immunoprecipitated material was of course reactive
with pAbL64 polyclonal antibodies (Figure 6b, lane 1) and
also with monoclonal antibodies mAb8H8 (lane 2) or
mAbJ28 (lane 3); therefore, BSDL in urines of a patient
afflicted with a pancreatic adenocarcinoma harbors the
pancreatic-specific J28 epitope. In the first instance, these
results suggest that BSDL in urine is representative of the
pancreatic glycoform.
If BSDL in urine comes from the pancreas, the enzyme
should transit via the blood and the kidney glomerulus.
Therefore, we have analyzed human kidney proteins. When
these proteins were separated on SDS-PAGE, transferred onto
nitrocellulose membrane and finally probed with pAbL64,
mAb8H8 or mAbJ28, no material migrating with the known
size of the pancreatic protein3 could be detected (Figure 6d)
whereas in tumoral pancreatic homogenate, BSDL was
reactive with these three antibodies (Figure 6c). These data
along with those demonstrating that no mRNA transcript
encoding BSDL can be detected in human adult kidney21
support that BSDL in urine originates from the blood. We
next attempted to localize BSDL in the human normal kidney
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Figure 4 | Urine BSDL last-purification step on SDS-PAGE. The
material eluted from the Sephacryl HRS-200 column was dialyzed
against water and lyophilized. The material was then analyzed on a
20 20 cm SDS-PAGE. After migration, a lane was cut off and
analyzed for immunodetection of pAbL64 reactive material. The
second lane (right lane) was colored with Coomassie blue. Four slices
were isolated from the colored material; each slice was then analyzed
by mass spectrometry.
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Figure 5 | MALDI mass spectrum of the tryptic digest of the
110 kDa gel slice. The full MS spectrum from 800–2700 m/z is given.
The identified BSDL peaks are labelled by the amino-acid sequences
in the MALDI mass spectrum. The total amino-acid sequence of
human pancreatic BSDL is given and the black bars indicate peptides
that were observed in the MALDI data. The framed sequence
corresponds to the O-glycosylated C-terminal domain of BSDL, which
cannot be digested by trypsin.
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using immunohistochemistry. For this purpose, serial
sections of human kidney were incubated with pAbL64 and
markers of distal convoluted tubules (mAb anti-EMA),
proximal tubules (mAb anti-vimentin) and endothelial cells
(mAb anti-CD34). The antibody–antigen complexes were
further detected with alkaline phosphatase-conjugated sec-
ondary antibodies. Distal convoluted tubules of the renal
cortex characterized by a strong and diffuse staining with
apical polarity with mAb anti-EMA were also stained by
pAbL64 (Figure 7a). Proximal tubules showed an expression
of vimentin at the basolateral membrane of cells, whereas
BSDL was not detected (Figure 7b). A diffuse staining pattern
was found in capillary arteries irrigating the glomerulus with
mAb anti-CD34 and pAbL64 (Figure 7c). No staining was
found in control sections without primary antibodies.
However, cells within this cortical area were unreactive with
these polyclonal antibodies supporting the fact that BSDL of
urines is not expressed by kidney cells. These data suggested
that circulating BSDL is filtered by the kidney glomerulus to
be eliminated in urines without reabsorption by the proximal
convoluted tubules.
Quantitation of BSDL in urines
Quantitation of BSDL using the enzyme-linked immunosor-
bent assay method previously described to quantitate BSDL
in sera22 did not give accurate results in urines. Therefore,
quantitation of BSDL in urine was performed by dot-blot
quantitations corrected for the unspecific reactivity (using
secondary antibodies alone) and reported to the immuno-
reactivity of a standard solution of BSDL. Under these
conditions, we can estimate that BSDL concentration in
urines of healthy subjects ranges between 1100 and 100 mg/l
(2907370 mg/l, n¼ 9). Compared to the concentration of
BSDL in serum as determined by enzyme-linked immuno-
sorbent assay, that is 1.5 mg/l, this result suggests that the
protein is efficiently filtrated and concentrated in urines.
Albumin was also determined by dot-blot dilution using anti-
human serum albumin (Sigma St Louis, MO). In our urine
samples, the serum concentration of albumin was within the
range of normal values, that is 1–5 mg/l (2.571.2 mg/l,
n¼ 9). From the literature, blood albumin concentration is
close to 35–50 g/l. Clearly, these data demonstrate that BSDL
is concentrated in urine.
DISCUSSION
This study provides evidences that the circulating BSDL,
which is of pancreatic origin,5 is in part eliminated from the
blood by renal filtration. BSDL is found in all urines
examined up to now and it is surprisingly intact and active
both on water-soluble 4-NPC and on micellar cholesteryl
esters. The presence of BSDL in urine was also ascertained by
Western blot using a specific monoclonal antibody to the
pancreatic enzyme. The protein was further isolated by
molecular sieving from urine of healthy subjects. Finally,
mass spectrometry allows unambiguous characterization of
the enzyme. Immunohistochemistry images suggested that
BSDL is concentrated in capillaries of Bowman’s capsule and
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Figure 6 | Immunodetection of the pancreatic isoform of BSDL in
urines and kidney. (a) mAbJ28 reactivity of human urines. Urines
(25ml) from the patient afflicted with an adenocarcinoma of the
pancreas were analyzed, after SDS-PAGE and electrotransferred on a
nitrocellulose membrane, for the reactivity with pAbL64 directed
against BSDL (lane 1), with mAb8H8 directed against normal
pancreatic BSDL (lane 2) and with mAbJ28 directed against the
oncofetal pancreatic glycoform of BSDL (lane 3). (b) Immunopreci-
pitation of urine BSDL with pAbL64 and immunodetection with
mAbJ28. Five hundred microliters of desalted and concentrated
urines from a patient suffering from an adenocarcinoma of the
pancreas were immunoprecipitated with 10 mg of pAbL64. Ten
microliters of immunoprecipitated material were loaded onto an
SDS-PAGE, electrotransferred on a nitrocellulose membrane and
probed with pAbL64 (lane 1), mAb8H8 (lane 2) and mAbJ28 (lane 3).
(c) Immunodetection of BSDL in tumoral human pancreatic
homogenate proteins. Human pancreatic homogenate (10mg of
protein per lane) was analyzed on SDS-PAGE as above and
immunodetected with pAbL64 (lane 1), mAb8H8 (lane 2) and mAbJ28
(lane 3). (d) Immunodetection of BSDL in human kidney proteins.
Medley kidney proteins (20mg of the commercial preparation) were
analyzed as in (c) and immunodetected with pAbL64 (lane 1),
mAb8H8 (lane 2) and mAbJ28 (lane 3).
a b c
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Figure 7 | Localization of BSDL in normal human kidney tissue.
BSDL was localized on sections of normal human kidney. For this
purpose, serial sections were incubated with (a, b, c, pAbL64 upper
panels), (a, lower panel) antibodies to EMA, (b, lower panel)
antibodies to vimentin and (c, lower panel) antibodies to CD34, and
revealed using the EnVision kit. pAbL64 reactivity can be localized (a)
in convoluted distal tubules and (c) in kidney arteriola, which are also
reactive to anti-EMA and anti-CD34, respectively. (b, upper and lower
panels) No reactivity with antibodies to vimentin that locates
proximal convoluted tubules was associated with that of pAbL64.
Controls (not shown) without antibodies were all negative (Original
magnification: 300).
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in distal convoluted tubules. Northern blots and reverse
transcriptase-polymerase chain reaction performed on renal
nucleic acids21 and immunodetection experiments support
that BSDL could be filtrated by the glomerulus and likely not
expressed by any cells of the kidney. A recent proteomic
profiling of low-density urinary membrane fractions pro-
duced by renal epithelial cells23 identified more than 250
proteins except BSDL. This suggests that BSDL might not
originate from renal epithelial cells. The first question is why
had BSDL not been detected in urine before this present
work? The main reason is likely that the detection method
used here is immunological and that previous studies
produced selective maps.24 Also two-dimentional electro-
phoreses profiling of proteins in urine followed by mass
spectrometry and sequence database searches generally
concern proteins of a size smaller than that of albumin (i.e.
o67 kDa).25
The glomerular capillary wall efficiently restricts the trans-
mural passage of proteins from the blood into Bowman’s
space. Therefore, the presence of BSDL, an anionic protein
(pIE4.2) of 110 kDa with a Strokes radius of approximately
53 A˚,12 in urine of healthy subjects is at least surprising.
This restricted filtration is based on molecular size,
electrical charge and sterical configuration.13 Large and
anionic proteins are less readily filtered than small and
positively charged molecules. The consensus is that the
glomerular wall may be constituted of three barriers. The first
barrier encountered by the filtrate is the open cylindrical
pores of the fenestrated glomerular endothelium.12,26 These
pores are mainly of small sizes, from 36 to 44 A˚ in radius.
However, a part of the pore population consisted of a limited
number of large pores with a radius of 80–90 A˚.13 The
glycocalyx that covers both pore and interfenestral domains is
likely to offer significant resistance to filtration of macro-
molecules.27 Underneath pores is the basement membrane, a
network of collagen and proteoglycans28 rich in anionic
heparan sulfate, which acts as an electric barrier hindering
anionic plasma proteins from going through the basement
membrane.29 After these two barriers, the filtrate goes
through the filtration slits established by the interdigitations
of podocyte feet that form the slit diaphragm. Much debate
has focused on which part of the glomerular filtration barrier
is primarily responsible for restricting protein flux, but
models indicate that the barrier functions as a whole with
each part making an essential contribution.26 In physiological
conditions, proteins with a size comparable to that of
immunoglobulin (e.g. with a molecular radius of 55 A˚) are
completely restricted from filtration because their radius is
larger than that of the small pores. In this filtration, the
contribution of large selective pores is quantitatively
irrelevant. The glomerular transmural passage of a protein
is examplified by the serum albumin. The low permeability of
the glomerular endothelium to this protein (radiusE36 A˚)
cannot be explained in terms of a simple restricted clearance
by pore size. Some characteristics of this protein, related in
part to its negative charge and consequently to its repulsion
by the anionic basement membrane of the glomerulus, result
in the restricted permeability of this protein. Hydrodynamic
properties of serum albumin in solution30 correlate with the
crystal structure31 and do not favor the transmural filtration
of the protein. These physicochemical characteristics of the
glomerular permselectively should preclude the passage of
BSDL. Therefore, the question is how is BSDL transmurally
transported from the blood to the urine. One possibility is
that BSDL first binds to the glycocalyx of the glomerular
endothelium via its heparin-binding site32 or its cationic
clusters.33 It may then diffuse through selective pores,
concentrate at the level of proteoglycans of the basement
membrane still by means of its affinity for heparans, and
finally filtrate through the slit diaphragm. Hydrodynamic
properties of the enzyme could be compatible with the
motion through the pores of the fenestrated endothelium.
Although the Strokes radius of BSDL is larger than the
permissive size of pores, one has to understand that this
concerns the gyration diameter of the hydrated protein (i.e.
the diameter of the sphere in which one BSDL molecule freely
rotates).12 This large spatial volume of BSDL is because of its
structure constituted of two distinct domains. The first is the
spherical N-terminal domain, where the two basic clusters
and the catalytic site are located. This globular domain,34
comprising residues 1–535, should have a radius lower than
38 A˚ corresponding to a spherical molecule with the same
mass. The second domain is the extended C-terminal mucin-
like region, which confers to BSDL its specific hydrodynamic
properties that are compatible with a problate ellipsoid (or
barrel structure) with a large gyration radius (453 A˚).12
Molecular modeling indicates that the N-terminal domain of
BSDL is a dipole with the positive potential culminating at
the N-terminal basic cluster.35 This cationic head, with the
extended C-terminal domain protruding on the opposite side
of the molecule may serve to guide the protein within the
pore and allow the attraction of the protein by heparan
sulfate of the basement membrane. This problate ellipsoid
with a strong dipole moment could be capable of migrating
through the pores of the fenestrated endothelium. The
hydrodynamic of fluxes in the glomerular capillary wall
should favor this motion. Another possibility is that BSDL
glomerular transit mimics what happens in the intestinal
wall, where the protein interacts with the glycocalyx present
on microvilli of the enterocytes, then concentrates at the level
of clathrin-coated pits and associates with the Lox-1 receptor
at the apical membrane.4 Finally, BSDL is transported up to
the baso-lateral membrane of enterocytes to reach the blood.
Therefore, the endothelial cells of the glomerulus that
expressed Lox-136 can capture BSDL. Consequently, BSDL
may shunt the cylindrical pores, being actively captured by
Lox-1 and transported up to the basement membrane and slit
diaphragm domain of podocytes to reach Bowman’s space
and primary urine. This suggests that the clearance of BSDL
from the blood could be an active receptor-mediated
mechanism. How BSDL moves through the basement
membrane and further through the zipper-like morphologic
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structure of the glomerular podocyte slit diaphragm remains
an open question. It is established that the vascular
endothelium growth factor (VEGF), expressed in podocyte
foot processes,37 increases the glomerular endothelial cell
permeability to small molecules, except serum albumin.38
What could be the relationship between BSDL, which is
capable to displace VEGF from the matrix,8,9 and this growth
factor at this level forms the foundation for in-depth studies.
Once in the proximal convoluted tubule, BSDL could be
reabsorbed by the epithelial cells of the pars convoluta. It is
assumed that this luminal endocytosis is initiated by binding
of ligands to binding proteins13 by means of cationic
clusters.39 Following this binding, BSDL like any other
proteins in primary urines can be directed to lysosomes for
degradation.40 However, we were unable to detect BSDL in
proximal convoluted tubules. Obviously, the enzyme is
present in glomerular capillaries and concentrated in distal
tubules. Furthermore, the presence of a large amount of
this protein in urines of healthy subjects does not support
the efficient reabsorption of BSDL by epithelial cells of
proximal convoluted tubules and agrees with the filtration of
this high-molecular weight blood glycoprotein by the
glomerulus.
MATERIALS AND METHODS
Materials
Alkaline phosphatase-labelled antibodies to rabbit and mouse
immunoglobulins were from Sigma (St Louis, MO, USA). Sephadex
G-25 and Sephacryl HRS-200 were from Amersham (Orsay, France).
Sequencing grade porcine trypsin was from Promega (Madison, WI,
USA). Polyclonal antibodies (pAbL64) raised against human BSDL,3
the monoclonal antibody (mAbJ28) which recognizes the fucosyl-
ated J28 glycotope carried by the C-terminal domain of the
oncofetal glycoisoform of the pancreatic BSDL41,42 and the
monoclonal antibody (mAb8H8) also directed against O-glycosyl-
ated C-terminal domain of BSDL (unpublished observation) were
obtained from our laboratory. The human kidney protein medley
came from Clontech (St Quentin, France). Human pancreatic tissue
homogenization has already been described.43
Samples
Urine samples of the first emission in the morning (10 ml) were
collected from 36 healthy male subjects (age 27–55 years) recruited
at the Centre Re´gional de De´pistage et de Pre´vention de
l’Athe´roscle´rose (Timone Hospital, Marseille, France). All patients
were in good condition, defined as the lack of recent clinical events.
They had normal blood pressure. None of them had proteinuria or
glucose as assayed by reagent strip analyses (Multistix 10SG, Bayer,
Bridgend, UK). All other biological parameters (hemoglobin,
bilirubin, urobilinogen) were null, and physicochemical parameters
(pH, gravity) were within the normal range. Nitrite and ketone were
absent. All patients had normal urine creatinine (11.374.2 mmol/
24 h).
A urine sample was collected under identical conditions from a
male patient (age 70 years) afflicted with a recent diagnosis of a
pancreatic cancer. This patient was not taking medication at the
time of urine collection. This sample was collected at the Surgery
Department (St Marguerite Hospital, Marseille, France). This
patient was selected for the absence of renal failure (normal urine
creatinine), the absence of proteinuria and glucose and the absence
of diagnosed diabetes at the time of collection.
Human kidney tissue was obtained from the normal tissue
portion after surgical nephrectomy of a patient suffering from
kidney cancer. The normal histology of the tissue was confirmed by
two independent examinations by anatomopathologists.
Immunohistochemistry
After resection, the kidney tissue was cut into 0.5 mm serial sections.
Sections were dried for 20 min at room temperature and fixed in
acetone at 41C for 10 min. After washing in 50 mM Tris/HCl pH 7.2
buffer, sections were incubated with or without (control) mono-
clonal (mAb) and polyclonal (pAb) antibodies: mAb anti-human
epithelial membrane antigen (anti-EMA, clone E29, DakoCyto-
mation, Glostrup, Denmark) 1/50 diluted, mAb anti-vimentin
(Immunotech, Beckman Coulter, Marseille, France), 1/25 diluted,
60 min at 371C, mAb anti-CD34 (Immunotech), pre-diluted, 60 min
at 371C, pAbL64, 90 min at 371C. The slides were then treated with
alkaline phosphatase-conjugated secondary antibodies (DakoCyto-
mation, EnVision kit) according to the manufacturer’s protocol. The
reaction was stopped with distilled water and sections were
counterstained with hematoxylin before microscope observation
and photography.
Enzyme activity and protein determinations
The esterolytic activity was recorded using 4-NPC as substrate.44
The cholesterol esterase activity was determined on cholesteryl
[14C]-oleate (LifeSciences, Zaventem, Belgium) as described.33
Protein concentration was determined with the bicinchoninic acid
test (Pierce, Rockford, IL, USA).
SDS-PAGE and immunoblottings
SDS-PAGE was performed in 10% polyacrylamide and 0.1% SDS as
described by Laemmli.45 After electrophoretic migration, proteins
were either labelled with Coomassie blue or electrotransferred onto
nitrocellulose membranes. Proteins were immunodetected using
pAbL64, mAbJ28 or mAb8H8 (1mg/ml) specific for human BSDL
pancreatic variants.42
Molecular sieving
Urines were centrifugated (15 min, 17 000 r.p.m.) and concentrated
by ultrafiltration (Centriprep YM-10, Millipore, Saint Quentin en
Yuelines, France). Desalting was then performed on a Sephadex
G-25 column (20 2.5 cm) eluted with distilled water (42 ml/h).
After the void volume (19 ml), protein fractions (20 ml) were pooled
and lyophilized. The lyophilized material was resuspended in 1 ml of
10 mM Tris/HCl pH 7.8 buffer (0.4 M NaCl) and loaded on a
Sephacryl HRS-200 column (120 1.5 cm) eluted with the same
buffer (25 ml/h). Fractions (1 ml) were collected and analyzed for
hydrolytic activity on 4-NPC and for immunoreactivity with
pAbL64. For this purpose, 1 ml of each fraction was dotted on a
nitrocellulose membrane and immunodetected.42 Immunoreactive
fractions associated with a hydrolytic activity on 4-NPC were
pooled, dialyzed against water and lyophilized before analyses. Dot-
blot quantitations were performed using the NIH image program
(http://rsb.info.nih.gov/nih-image/).
Immunoprecipitation
Desalted urines were incubated overnight at 41C with 10 mg pAbL64.
Pre-washed protein A-Sepharose (20 mg, Amersham) was added to
antibody-antigen complexes and incubated (4 h, 41C) under
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agitation. At the end of the incubation, the antibody–antigen–pro-
tein A complexes were recovered and washed as described.46 The
final pellet was transferred into Laemmli’s sample buffer45 and
analyzed on SDS-PAGE. Proteins were then electrotransferred onto a
nitrocellulose membrane and immunodetected with adequate
primary antibodies.
Mass spectrometry
Large (20 20) cm SDS-PAGE were performed to optimize the
protein separation. The migration was run on an SDS-PAGE device
from Fisher (Illkirch, France) overnight at 41C and 100 mA. After
migration, one lane was cut off and electrotransferred onto a
nitrocellulose membrane and probed with pAbL64; other lanes were
stained with Coomassie blue, protein bands were excised, destained
and in-gel digested47 with trypsin (20 mg/ml in 10 mM Tris/HCl pH 9
buffer). Peptides were extracted, dried in a vacuum centrifuge and
redissolved in 10–20 ml of 5% formic acid before mass analyses. One
microliter of the peptide mixture was co-crystallized on the MALDI
target with an equal volume of the matrix solution (10–20 g/l of
a-cyano-4-hydroxycinnamic acid in 70% acetonitrile).25 The digest
was analyzed on an EttanPro spectrometer (Amersham). Proteins
were identified by the Profound (ProteoMetrics, New York, NY, USA)
and the Mascot softwares (MatrixScience, London, UK), that correlate
mass spectometry data with comprehensive sequence databases.
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